OncoMatch/Clinical Trials/NCT06056336
Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Is NCT06056336 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Tislelizumab for esophageal squamous cell carcinoma.
Treatment: Tislelizumab — The purpose of this study is to analyze esophageal cancer patients who underwent neoadjuvant immunotherapy with chemotherapy followed by esophagectomy to determine whether additional adjuvant therapy is associated with improved survival outcomes.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage CT1B-3N1-3M0, T3N0M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: radiotherapy
any radiotherapy, chemotherapy or other antineoplastic drugs directed at the tumour
Cannot have received: chemotherapy
any radiotherapy, chemotherapy or other antineoplastic drugs directed at the tumour
Cannot have received: antineoplastic drugs
any radiotherapy, chemotherapy or other antineoplastic drugs directed at the tumour
Cannot have received: immunosuppressive drug
Exception: inhaled or topical steroids and corticosteroid replacement at doses >10mg/day of prednisone or equivalent were allowed in the absence of active autoimmune disease
being treated with an immunosuppressive drug or systemic hormone for immunosuppression (at a dose of >10mg/ day of prednisone or equivalent) within 2 weeks before the first dose of the study drug
Cannot have received: systemic hormone for immunosuppression
Exception: inhaled or topical steroids and corticosteroid replacement at doses >10mg/day of prednisone or equivalent were allowed in the absence of active autoimmune disease
being treated with an immunosuppressive drug or systemic hormone for immunosuppression (at a dose of >10mg/ day of prednisone or equivalent) within 2 weeks before the first dose of the study drug
Cannot have received: live attenuated vaccine
received live attenuated vaccine within 4 weeks before the first dose of study drug
Cannot have received: major surgery or severe trauma
major surgery or severe trauma within 4 weeks before the first dose of study drug
Cannot have received: anti-PD-1 therapy
Patients have previously received an anti-PD-1, PD-L1 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: anti-PD-L1 therapy
Patients have previously received an anti-PD-1, PD-L1 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Cannot have received: checkpoint inhibitor
Patients have previously received an anti-PD-1, PD-L1 or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
Lab requirements
Blood counts
white blood cells > 4×10^9/L, neutrophil > 1.5 ×10^9/L, hemoglobin > 90g/L, platelets > 100×10^9/L
Kidney function
GFR >60 mL/min; serum creatinine (SCr) ≤120 μmol/L
Liver function
AST, ALT ≤ 3× ULN; total bilirubin <1.5× ULN; AST and ALT <2.5× ULN
Cardiac function
adequate cardiac function; ECG for all; echocardiography with LVEF >50% if cardiac history or ECG abnormality
Adequate cardiac function... Adequate respiratory function with FEV1 ≥ 1.2 L, FEV1% ≥ 50% and DLCO ≥ 50%... Adequate bone marrow function (white blood cells > 4×10^9/L, neutrophil > 1.5 ×10^9/L, hemoglobin > 90g/L, platelets > 100×10^9/L). Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 3× upper level of normal (ULN); Adequate liver function (total bilirubin <1.5× ULN, AST and ALT <2.5× ULN); Adequate renal function (GFR >60 mL/min; serum creatinine (SCr) ≤120 μmol/L)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify